Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9–10 clinical localized prostate cancer

As several recent researches focus on the importance of Gleason 9–10, we examine the role of radiotherapy dose escalation in those patients. We analyzed 476 patients with Gleason score 9–10 prostate cancer treated with radiotherapy. Of them, 127 patients were treated with conventional-dose external...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2022-01, Vol.12 (1), p.268-268, Article 268
Main Authors: Yamazaki, Hideya, Suzuki, Gen, Aibe, Norihiro, Shimizu, Daisuke, Kimoto, Takuya, Masui, Koji, Yoshida, Ken, Nakamura, Satoaki, Okabe, Haruumi
Format: Article
Language:English
Subjects:
692/4028
692/4028/67/589
Aged
Aged, 80 and over
Brachytherapy
Brachytherapy - adverse effects
Brachytherapy - mortality
Disease-Free Survival
Humanities and Social Sciences
Humans
Japan
Male
Metastases
Middle Aged
multidisciplinary
Neoplasm Grading
Patients
Prostate cancer
Prostatic Neoplasms - mortality
Prostatic Neoplasms - pathology
Prostatic Neoplasms - radiotherapy
Radiation therapy
Radiotherapy Dosage
Radiotherapy, Intensity-Modulated - adverse effects
Radiotherapy, Intensity-Modulated - mortality
Retrospective Studies
Science
Science (multidisciplinary)
Survival
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As several recent researches focus on the importance of Gleason 9–10, we examine the role of radiotherapy dose escalation in those patients. We analyzed 476 patients with Gleason score 9–10 prostate cancer treated with radiotherapy. Of them, 127 patients were treated with conventional-dose external beam radiotherapy (Conv RT) and 349 patients were treated with high-dose radiotherapy (HDRT; 249 patients received high-dose-rate brachytherapy boost + external beam radiotherapy [HDR boost] and 100 patients received intensity-modulated radiotherapy [IMRT]). We compared these treatment groups using multi-institutional retrospective data. The patients had a median follow-up period of 66.3 months. HDRT showed superior biochemical disease-free survival (bDFS) rate (85.2%; HDR boost 84.7% and IMRT 86.6%) to Conv RT (71.1%, p  
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-04233-4